December #108 : Moonlighting Statins - by David Gelman, MD

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Detectable Rebels

Now See This

Editor's Letter-December 2004

Mailbox-December 2004

Down on the Pharma

Show and Tell

Pushing the Envelope

First, the Bad News


Faster Forward

Prince Valiant


Pregnant Pauses

Moonlighting Statins

They Soothe Tootsies, Don’t They?

Trouble in Mind

Pharm School

View from the Top

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

December 2004

Moonlighting Statins

by David Gelman, MD

Can cholesterol-lowering drugs reduce your viral load, too?

T he big-deal Journal of Experimental Medicine dropped a bombshell in August: Cholesterol-lowering statin meds may also reduce HIV viral load. Mevacor (lovastatin) inhibited HIV in a test tube, so Spanish researchers gave six HIVers (who’d never taken HAART ) 40 mg per day for one month. Viral loads fell in all six, though on average only by a factor of 4 (0.6 log)—most antivirals cause a drop of tenfold or more. “Absolutely fascinating,” says San Fran HIV doc Mary Romeyn, MD, who thinks the statins may do it indirectly by shrinking inflammation. The study poses promising questions:

Is the effect limited to Mevacor? The researchers think that any statin would lessen viral load.

Is the result durable? The monthlong study was too short to reveal whether HIV can mutate to escape the statins.

Why has this gone unnoticed until now—with so many HIVers taking statins? Only a larger trial will tell.

Have statins confounded earlier med studies? In many trials, participants take statins if HAART hikes their cholesterol. The HIV meds in the study would have been credited for any drop in these HIVers’ viral loads. (And HIV study pro Cal Cohen, MD, says he can’t recall any trial where data suggested a statin-induced viral-load decrease.)

Mevacor’s Merck and Lipitor’s Pfizer declined comment, but HIV docs let rip: “Not convincing,” says Keith Henry, MD, of the University of Minnesota, because the test-tube results were more dramatic than the human benefit. Cohen says he hasn’t seen signs of this effect in statin-taking patients. And Cornell’s Marshall Glesby, MD, warns, “There’s a potential for serious toxicity from interactions between certain statins and protease inhibitors.” As always, check with Doc before statin anything new.—

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.